公开(公告)号：US20240299368A1

公开(公告)日：2024-09-12

申请号：US18667886

申请日：2024-05-17

申请人： SALIX PHARMACEUTICALS, INC.

发明人： William Forbes

IPC分类号： A61K31/437 ,  A61K31/08 ,  A61K31/352 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/7016 ,  A61K31/785 ,  A61K38/14 ,  A61K38/31 ,  A61K45/06

CPC分类号： A61K31/437 ,  A61K31/08 ,  A61K31/352 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/7016 ,  A61K31/785 ,  A61K38/14 ,  A61K38/31 ,  A61K45/06

摘要： The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

公开(公告)号：US20240216389A1

公开(公告)日：2024-07-04

申请号：US18604451

申请日：2024-03-13

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： Hiroyuki FUJIKI ,  Miki Aihara ,  Shizuo Kinoshita

IPC分类号： A61K31/55 ,  A61K9/00 ,  A61K38/10 ,  A61K38/31 ,  A61K45/06

CPC分类号： A61K31/55 ,  A61K9/0019 ,  A61K9/0053 ,  A61K38/10 ,  A61K38/31 ,  A61K45/06

摘要： An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.

公开(公告)号：US11857604B2

公开(公告)日：2024-01-02

申请号：US16755866

申请日：2018-10-12

申请人： NH THERAGUIX ,  Universite Claude Bernard Lyon 1 ,  Centre National de La Recherche Scientifique—CNRS—

发明人： Olivier Tillement ,  François Lux ,  Fabien Rossetti ,  Vu-Long Tran ,  Clélia Mathieu ,  Myleva Dahan

IPC分类号： A61K38/31 ,  A61K47/69 ,  A61P35/00 ,  A61K33/243 ,  A61K9/14 ,  A61K31/704 ,  A61K49/00 ,  A61K49/12 ,  A61K49/18 ,  B82Y5/00 ,  A61K33/244 ,  A61K9/00

CPC分类号： A61K38/31 ,  A61K9/146 ,  A61K31/704 ,  A61K33/243 ,  A61K33/244 ,  A61K47/6929 ,  A61K49/0002 ,  A61K49/128 ,  A61K49/1881 ,  A61P35/00 ,  B82Y5/00 ,  A61K9/0019

摘要： The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.

公开(公告)号：US11723868B2

公开(公告)日：2023-08-15

申请号：US17102919

申请日：2020-11-24

申请人： Adare Pharmaceuticals USA, Inc.

发明人： Nathan Dormer ,  Cory Berkland

IPC分类号： A61K9/16 ,  A61K9/00 ,  A61K31/00 ,  A61K45/06 ,  A61K9/19 ,  A61K31/47 ,  A61P3/02 ,  A61P5/24 ,  A61P33/02 ,  A61P43/00 ,  A61K31/567 ,  A61K38/31 ,  A61P31/18 ,  A61P35/00

CPC分类号： A61K9/1652 ,  A61K9/0019 ,  A61K9/1647 ,  A61K31/00 ,  A61K45/06 ,  A61K9/19

摘要： Novel microsphere compositions for use in parenteral formulations are provided. The microspheres comprise a biodegradable polymer of a molecular weight greater than 10,000 daltons, an active therapeutic agent, and a cellulose-derived material such as ethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, or sodium carboxymethyl cellulose. The microsphere compositions decreased deviation in mean microsphere diameter, improved drug entrapment, and improved microsphere stability.

公开(公告)号：US11633384B2

公开(公告)日：2023-04-25

申请号：US17213678

申请日：2021-03-26

申请人： Salix Pharmaceuticals, Inc.

发明人： William Forbes

IPC分类号： A61K31/437 ,  A61K31/08 ,  A61K31/352 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/7016 ,  A61K31/785 ,  A61K38/14 ,  A61K38/31 ,  A61K45/06

摘要： The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

公开(公告)号：US20230053812A1

公开(公告)日：2023-02-23

申请号：US17875117

申请日：2022-07-27

申请人： Aurobindo Pharma Ltd

发明人： Saravanan KANNUSAMY ,  Prabhakaran CHAKKIRALA ,  Raghavendra Bharat GUNDA ,  Nagaprasad VISHNUBHOTLA ,  Meenakshisunderam SIVAKUMARAN

IPC分类号： A61K38/26 ,  A61K9/20 ,  A61K38/31 ,  A61K9/48 ,  A61K9/00 ,  A61K47/22 ,  A61K38/28 ,  A61K38/22 ,  A61K38/095 ,  A61K38/23 ,  A61K38/29 ,  A61K31/401

摘要： The invention relates to stable pharmaceutical formulation useful for the oral administration comprising a peptide or protein drug and a permeation enhancer. In particular, the invention relates to stabilized pharmaceutical formulations comprising GLP-1 receptor agonist such as Semaglutide and a permeation enhancer and its process for preparation.

公开(公告)号：US20220233630A1

公开(公告)日：2022-07-28

申请号：US17721725

申请日：2022-04-15

申请人： Amryt Endo, Inc.

发明人： Roni MAMLUK ,  Sam Teichman

IPC分类号： A61K38/08 ,  A61K38/31 ,  A61K9/48 ,  A61P5/06 ,  A61K9/00

摘要： Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

公开(公告)号：US20220213483A1

公开(公告)日：2022-07-07

申请号：US17700339

申请日：2022-03-21

申请人： Regulus Therapeutics Inc. ,  The Board of Regents of The University of Texas System

发明人： Charles R. ALLERSON ,  Vishal D. PATEL ,  B. Nelson CHAU ,  John R. ANDROSAVICH

IPC分类号： C12N15/113 ,  A61P13/12 ,  A61K9/08 ,  A61K31/436 ,  A61K31/496 ,  A61K31/517 ,  A61K31/55 ,  A61K31/585 ,  A61K31/7125 ,  A61K38/22 ,  A61K38/31 ,  A61K45/06

摘要： Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

公开(公告)号：US11141385B2

公开(公告)日：2021-10-12

申请号：US17012783

申请日：2020-09-04

申请人： THE SCRIPPS RESEARCH INSTITUTE

发明人： Jiajia Dong ,  K Barry Sharpless ,  Jeffery W. Kelly ,  Aleksandra Baranczak ,  Wentao Chen

IPC分类号： C07D501/18 ,  A61K31/05 ,  C07C305/26 ,  C07D277/82 ,  C07D295/088 ,  C07D295/185 ,  C07D295/26 ,  A61K47/54 ,  C07D279/08 ,  A61K31/136 ,  A61K31/14 ,  A61K31/197 ,  A61K31/198 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4245 ,  A61K31/4353 ,  A61K31/439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/485 ,  A61K31/505 ,  A61K31/515 ,  A61K31/53 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/65 ,  A61K31/655 ,  A61K31/70 ,  A61K31/7048 ,  A61K38/31 ,  A61K51/04 ,  C07K1/02 ,  C07K1/113 ,  C07K2/00

摘要： This application describes a compound represented by Formula (I): wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

公开(公告)号：US20210308226A1

公开(公告)日：2021-10-07

申请号：US17350363

申请日：2021-06-17

申请人： CAMURUS AB

发明人： Fredrik Tiberg ,  Catalin Nistor ,  Markus Johnsson

IPC分类号： A61K38/31 ,  A61K47/10 ,  A61K9/00 ,  A61K9/127 ,  A61K47/14 ,  A61K47/24

摘要： The present invention relates to compositions forming a low viscosity mixture of: a)
20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b)
20-80 wt. % of at least one phosphatidyl choline (PC); c)
5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d)
up to 20 wt. % polar solvent e)
at least one peptide active agent; f)
optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.